These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25407559)

  • 1. A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.
    Blumenthal DT; Rankin C; Stelzer KJ; Spence AM; Sloan AE; Moore DF; Padula GD; Schulman SB; Wade ML; Rushing EJ
    Int J Clin Oncol; 2015 Aug; 20(4):650-8. PubMed ID: 25407559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
    Butowski N; Chang SM; Lamborn KR; Polley MY; Pieper R; Costello JF; Vandenberg S; Parvataneni R; Nicole A; Sneed PK; Clarke J; Hsieh E; Costa BM; Reis RM; Hristova-Kazmierski M; Nicol SJ; Thornton DE; Prados MD
    Neuro Oncol; 2011 Dec; 13(12):1331-8. PubMed ID: 21896554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
    Buckner JC; Ballman KV; Michalak JC; Burton GV; Cascino TL; Schomberg PJ; Hawkins RB; Scheithauer BW; Sandler HM; Marks RS; O'Fallon JR; ;
    J Clin Oncol; 2006 Aug; 24(24):3871-9. PubMed ID: 16921039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
    Balaña C; Ramirez JL; Taron M; Roussos Y; Ariza A; Ballester R; Sarries C; Mendez P; Sanchez JJ; Rosell R
    Clin Cancer Res; 2003 Apr; 9(4):1461-8. PubMed ID: 12684420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Friedman HS; Pluda J; Quinn JA; Ewesuedo RB; Long L; Friedman AH; Cokgor I; Colvin OM; Haglund MM; Ashley DM; Rich JN; Sampson J; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Stewart ES; Tourt-Uhlig S; Garcia-Turner AM; Herndon JE; Bigner DD; Dolan ME
    J Clin Oncol; 2000 Oct; 18(20):3522-8. PubMed ID: 11032594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
    Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
    Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
    Halperin EC; Herndon J; Schold SC; Brown M; Vick N; Cairncross JG; Macdonald DR; Gaspar L; Fischer B; Dropcho E; Rosenfeld S; Morowitz R; Piepmeier J; Hait W; Byrne T; Salter M; Imperato J; Khandekar J; Paleologos N; Burger P; Bentel GC; Friedman A
    Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):793-802. PubMed ID: 8598355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
    Pan E; Mitchell SB; Tsai JS
    J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
    Barrié M; Couprie C; Dufour H; Figarella-Branger D; Muracciole X; Hoang-Xuan K; Braguer D; Martin PM; Peragut JC; Grisoli F; Chinot O
    Ann Oncol; 2005 Jul; 16(7):1177-84. PubMed ID: 15857844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
    Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
    J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Kurpad SN; Dolan ME; McLendon RE; Archer GE; Moschel RC; Pegg AE; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(4):307-16. PubMed ID: 9025771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
    Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
    J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
    Marathi UK; Dolan ME; Erickson LC
    Biochem Pharmacol; 1994 Nov; 48(11):2127-34. PubMed ID: 7802703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
    Jaeckle KA; Ballman KV; Giannini C; Schomberg PJ; Ames MM; Reid JM; McGovern RM; Safgren SL; Galanis E; Uhm JH; Brown PD; Hammack JE; Arusell R; Nikcevich DA; Morton RF; Wender DB; Buckner JC
    J Neurooncol; 2010 Aug; 99(1):73-80. PubMed ID: 20063115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
    Adams DM; Zhou T; Berg SL; Bernstein M; Neville K; Blaney SM;
    Pediatr Blood Cancer; 2008 Mar; 50(3):549-53. PubMed ID: 17941066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
    Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
    J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.